Citadel Advisors’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Citadel Advisors’s Portfolio OPNT Stock Details OPNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-14,169	Closed	-$287K	–	16090
2022 Q4	$287K	Buy	+14,169	New	+$217K	﹤0.01%	9412
2021 Q2	–	Sell	-11,110	Closed	-$118K	–	14732
2021 Q1	$118K	Sell	11,110 -1,525	-12%	-$17.4K	﹤0.01%	12326
2020 Q4	$102K	Buy	+12,635	New	+$99.4K	﹤0.01%	10214

Citadel Advisors's OPNT Position: Q1 2023 in Review

Citadel Advisors sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q1 2023, closing a stake of 14,169 shares — an estimated $287K sold.

Citadel Advisors first reported a position in OPNT in Q4 2020 and held it in 3 quarters. The position peaked at $287K in Q4 2022. 0 funds tracked by Wall St. Rank hold OPNT as of Q1 2023.

Citadel Advisors reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Citadel Advisors sold 14,169 Opiant Pharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $287K.
Citadel Advisors first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
Citadel Advisors's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $287K in Q4 2022.
0 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.